MedPath

Comparative Bioavailability of Midazolam 7.5 mg/1.5 mL Oromucosal Solution (Buccolam®) Versus 10 mg/2 mL Solution for Injection (Hypnovel®) in Healthy Subjects.

Phase 1
Conditions
o medical condition.
Therapeutic area: Not possible to specify
Registration Number
CTIS2023-504903-10-00
Lead Sponsor
aboratorios Lesvi S.L.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath